Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Author(s) -
Neşe Demirtürk,
Bilgehan Aygen,
İ̇lhami Çelik,
Reşit Mıstık,
Sıla Akhan,
Şener Barut,
Onur Ural,
Ayşe Batırel,
Funda Simsek,
Gülden Ersöz,
Dilara İnan,
Sami KINIKLI,
Nesrin Türker,
Huseyin Bilgin,
Yunus Gurbuz,
Necla Tülek,
Hüseyin Tarakçı,
Orhan Yıldız,
Emine Türkoğlu,
Deniz Kamalak Guzel,
Sumeyra Simsek,
Nazan Tuna,
Nazlım Aktuğ Demir,
Atahan Çağatay,
Rıza Aytaç Çeti̇nkaya,
Faruk Karakeçili,
İ̇smail Necati Hakyemez,
Günay Tuncer Ertem,
Bahar Örmen,
Pınar Korkmaz,
Uluhan Yildiz,
Ziya Kuruüzüm,
Alper Şener,
Selcan Arslan Özel,
Sinan Öztürk,
Kaya Süer,
Mustafa Kemal Çelen,
Petek Konya,
Ali Aşan,
Neşe Saltoğlu,
Nurhan DOĞAN
Publication year - 2020
Publication title -
the turkish journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
pISSN - 1300-4948
DOI - 10.5152/tjg.2020.19569
Subject(s) - medicine , sofosbuvir , ribavirin , ledipasvir , hepatitis c , chronic hepatitis , virology , virus
In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom